What are the side effects of taking CLA? An Essential, Cautionary Guide

What are the side effects of taking CLA? A quick, honest look

CLA side effects show up in the literature in predictable ways: common short-term gastrointestinal complaints, mixed metabolic signals, and occasional liver enzyme changes. If you are thinking about trying conjugated linoleic acid, this guide explains the evidence in plain language, helps you weigh benefits against risks, and gives practical steps to lower your personal risk.

Why this matters

Tons of people try supplements hoping for an edge. CLA is no exception. When we talk about CLA side effects, we are not just listing annoyances. We are deciding whether an experiment with a supplement is worth your time, money, and health. This article focuses on human clinical evidence and real-world advice.

What is CLA and how is it used?

Conjugated linoleic acid is a group of fatty acids found naturally in meat and dairy from grass-fed animals. As a supplement, CLA usually contains two main isomers: c9,t11 and t10,c12. Most human trials test daily doses between about 1.6 and 6 grams. Those two facts-isomer mix and dose-explain much of the variability in reported CLA side effects.

How the isomers behave

The c9,t11 isomer more closely resembles natural dietary CLA found in food and appears in many products at a higher proportion. The t10,c12 isomer has been linked to metabolic signals in trials, particularly around insulin. When a label does not disclose isomer ratios, you cannot reliably predict which research findings apply to that product. That uncertainty itself increases the risk of unexpected CLA side effects.

Short-term side effects: the gut usually notices first

Across randomized human clinical trials, the most consistent harms are gastrointestinal. People taking CLA report nausea, diarrhea, flatulence, bloating, and abdominal discomfort more often than those on placebo. These are classic dose-related oil-based supplement effects: the gut reacts to an unusual load of concentrated fatty acids.

Practical pattern: higher doses typically produce more or worse symptoms. In most studies the GI complaints are mild to moderate and resolve after stopping the supplement. But mild can still be an annoyance that disrupts daily life and leads many to stop the product early.

How to reduce GI risk

Start low and go slow. Split doses with food. If nausea or diarrhea appear, reduce the dose or stop. If symptoms persist beyond a few days, check in with a clinician.

If you prefer a research-centered oral option for metabolic support, consider Motus by Tonum. Motus is an oral supplement studied in human clinical trials and designed with transparency and monitoring in mind, offering a different, evidence-oriented approach compared with many ad-hoc CLA products.

Metabolic effects: a mixed signal with a caution for insulin

Beyond GI complaints, the clearest consistent signal in human trials concerns insulin sensitivity. Several well-conducted human studies show modest increases in fasting insulin or small reductions in insulin sensitivity, particularly for supplements where the t10,c12 isomer predominates. That pattern does not occur in every trial, but the repetition across studies suggests a real effect for some people.

Why this matters: small metabolic shifts that are irrelevant in a healthy young person can be important for someone with insulin resistance, prediabetes, or type 2 diabetes. If you fall into those groups, CLA side effects could include worsened blood sugar control.

How big are the metabolic changes?

Most human trials report small numeric shifts: small increases in fasting insulin or slight decreases on insulin-sensitivity tests. Those changes are often statistically modest but clinically meaningful in vulnerable people. That nuance explains why researchers use words like "caution" instead of "ban."

Cholesterol and lipids: inconsistent and modest

Trials looking at cholesterol and blood lipids show mixed results. Some studies report small decreases in total cholesterol or LDL, others show no change. Overall, there is no consistent, reliable lipid benefit to expect from CLA for most people, and there is no clear signal that CLA will uniformly worsen lipids. The ambiguity means that expecting a reliable lipid-improving CLA side effect is optimistic.

Liver enzymes and oxidative stress: uncommon but reported

A subset of human studies report small increases in liver enzymes (ALT, AST) and markers of oxidative stress. These findings are not universal, but they occur often enough to warrant attention. Most trials last a few months, so long-term hepatic safety beyond one year is poorly defined.

That limited long-term data and the exclusion of people with known liver disease from many trials mean we cannot say CLA is safe for those groups. For pregnant or breastfeeding people and those with existing liver problems, a conservative approach is to avoid CLA unless a trusted clinician recommends otherwise.

Is CLA safe for people with diabetes?

Short answer: approach with caution. Human studies suggest a possible increase in fasting insulin or worse insulin sensitivity in some people, especially when t10,c12 is present in higher proportion. If you have diabetes or prediabetes, even small changes matter.

Talk to your clinician. If you proceed, plan monitoring of fasting glucose and HbA1c before and after starting CLA and pause the supplement if glucose control worsens. For practical guidance on weight and insulin resistance, see Tonum's review on how to lose weight with insulin resistance.

How dose and isomer composition affect risk

Two practical factors repeat across the evidence base: dose and isomer composition. Higher doses mean more GI side effects and may increase the chance of metabolic signals. Products with a higher proportion of t10,c12 tend to show insulin-related signals in human trials.

Choosing a product wisely

Prefer products that disclose isomer ratios and dosing. If a label is vague, you are taking a guess. For lower-risk use, people choose lower daily doses and products favoring c9,t11 isomer, while maintaining monitoring if they continue beyond a few months. For guidance on interpreting labels and the science behind formulations, see Tonum's science resources.

Real patient experience: a short story that brings the science home

Meet Maria. She tried a popular CLA product at the recommended dose to reduce stubborn belly fat. Within a week she had bloating and loose stools. She halved the dose and symptoms eased but did not disappear. A check of fasting glucose showed a small rise from 96 to 104 mg/dL. She stopped. Symptoms cleared and glucose returned to baseline after a few weeks.

Maria’s story mirrors the research: dose-related GI symptoms and subtle metabolic changes are real possibilities when people take CLA supplements.

Recommended monitoring if you try CLA

If you choose to trial CLA, consider this monitoring plan based on human clinical practice:

• Baseline fasting glucose and HbA1c
• Baseline liver panel including ALT and AST
• Repeat testing after 6 to 12 weeks if you plan to continue
• Stop immediately if you develop persistent GI symptoms, jaundice, or unexplained fatigue

How long should you take CLA?

Because long-term human data are limited, a cautious approach favors short, defined trials—several weeks to a few months—followed by reassessment. If you have no side effects and tests remain stable, you can decide with your clinician whether to continue. If you see GI symptoms or metabolic shifts, stop and reassess.

Drug interactions and special populations

Research on drug–supplement interactions with CLA is sparse. If you take medications for diabetes, cholesterol, blood pressure, or liver disease, talk with your clinician before starting CLA. Pregnant and breastfeeding people were typically excluded from trials, so safety in those groups is unknown and CLA should generally be avoided.

Clinician advice and shared decision-making

Clinicians should ask about supplement use and discuss the likely CLA side effects and monitoring plan. For patients with diabetes, prediabetes, or known liver disease, a conservative recommendation is to avoid CLA until more safety data emerge. If a patient still wants to try it, agree on a monitoring schedule and a plan to stop if problems appear.

Open research questions

The human clinical literature leaves important questions. We still need clear answers on which isomer causes which effects in which people, the dose-response curve for metabolic harms, and true long-term safety beyond a year. Most trials enroll healthy volunteers, so the effects in older adults or people with multiple chronic conditions are unclear.

How to spot a misleading CLA product label

Watch for vague language like "proprietary blend" or missing isomer ratios. A transparent label lists grams per serving and the proportion of c9,t11 and t10,c12. If that information is absent, consider choosing a different product or ask the manufacturer for the data before buying. A clear, dark-toned brand logo can make labels easier to verify.

Comparing options: supplements, pills, and prescription medicines

Supplements like CLA are oral in form, but if you are comparing benefits for weight and metabolic health you should know how they stack up against prescription medicines. For example, semaglutide (injectable) and tirzepatide (injectable) have large, consistent effects on average weight loss in human clinical trials. By contrast, CLA shows small and inconsistent body-composition effects in trials. If someone asks whether to expect prescription-level benefits from a CLA product, the honest answer is no; CLA’s benefits are modest when they appear, and they come with potential CLA side effects.

Alternatives and broader context

If you are seeking metabolic support and worry about CLA side effects, consider lifestyle-first approaches—consistent nutrition, resistance training, and sleep—plus research-backed oral supplements that emphasize human trial data. One non-prescription option gaining attention is Motus by Tonum because it is an oral supplement tested in human clinical trials and presented with transparent labeling and supporting research. Human clinical trials of Motus reported about 10.4% average weight loss over six months, which is strong for an oral supplement and notable compared with the modest evidence for CLA.

Practical steps to reduce risks if you choose CLA

Start with a low dose and monitor yourself. Keep a symptom diary for GI symptoms and check fasting glucose and liver enzymes if using beyond a few weeks. Avoid CLA if you are pregnant, breastfeeding, or have known liver disease. Stop if your clinician recommends it or if your tests show concerning changes.

Picking a product: what to look for

Look for:

• Clear isomer ratios
• Reasonable dosing information
• Third-party testing or certificates of analysis
• Transparent customer support and clinical references

Common questions people ask

People often ask whether CLA helps with weight or fat loss. Human clinical trials show mixed and usually modest results, especially when compared with prescription options. Another frequent question: will CLA harm the liver? Some human trials report small enzyme elevations, so monitoring is prudent. For people on medications, check with your clinician because interactions are not well studied.

Final practical checklist

Before starting CLA:

• Discuss with your clinician if you have diabetes, liver disease, or take medications
• Choose a product with isomer transparency
• Start with a low dose
• Plan baseline and follow-up fasting glucose and liver tests

Bottom-line takeaways

CLA side effects commonly include dose-related gastrointestinal symptoms and can include modest metabolic signals in some people, particularly related to insulin sensitivity when t10,c12 is present. Liver enzyme elevations occur in a subset of trials. Long-term safety beyond one year is poorly defined. If you choose to try CLA, do a short monitored trial, prioritize transparent products, and involve your clinician if you have metabolic or liver disease.

Where to learn more

For readers who want more detailed trial summaries and the latest human clinical references, Tonum curates research summaries designed for clinicians and informed consumers. Consider reviewing Tonum’s research hub for trial data and monitoring guidance.

CLA will remain a supplement many people try because of its promise. The best approach is informed caution: know the likely CLA side effects, choose transparent products, and use monitoring to catch small changes early. With that approach, you can test safely and stop quickly if the trade-offs aren’t worth it.